Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.090
Filtrar
1.
Medicine (Baltimore) ; 98(43): e17645, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31651884

RESUMO

Elabela is a bioactive peptide and a part of Apelinergic system. Elabela has an important role in the early embryonic stages. Elabela's beneficial effects in cardiovascular system were shown in some animal models or in vitro studies. Lately, some investigational studies in humans are started to be seen in literature. Our aims were to investigate serum Elabela levels in the first day of ST segment elevation myocardial infarction (STEMI), to compare with healthy controls, and to see if there is a correlation between other cardiac biomarkers in humans.The study was planned as cross-sectional. The patients group had 124 STEMI subjects. They were grouped as inferior (n = 59) and anterior myocardial infarction (n = 65) groups, and compared with the healthy control population (n = 77). Routine blood tests and serum Elabela levels were measured. Transthoracic echocardiography performed to all subjects.Frequency of diabetes mellitus, hypertension, smoking, and hyperlipidemia in both STEMI groups were significantly higher than control subjects. Glucose, high density lipoprotein (HDL) cholesterol, triglyceride, high sensitive C reactive protein (Hs-CRP), troponin I, N-terminal brain natriuretic peptide (NT-ProBNP), and Elabela levels were significantly higher in both STEMI groups. Other laboratory parameters were similar. Group 2 and 3 had significantly lower left ventricular ejection fraction (LVEF) than group 1. Group 3 had also significantly lower LVEF than group 2. There was a positive but moderate correlation between Elabela, troponin I, and NT-ProBNP. Elabela was negatively correlated with LVEF. This correlation was also moderate.We showed increased Elabela levels in STEMI patients in this study. Also, we observed a moderate positive correlation between troponin I, NT-ProBNP, and Elabela.


Assuntos
Hormônios Peptídicos/sangue , Infarto do Miocárdio com Supradesnível do Segmento ST/sangue , Biomarcadores/sangue , Estudos Transversais , Ecocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
3.
Curr Obes Rep ; 8(2): 77-87, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31037612

RESUMO

PURPOSE OF REVIEW: The goals of this paper are to report current research practices in investigations of human appetite control and to assess their relationships with emerging theoretical principles. Appetite is often distinguished by the separation of homeostatic and hedonic processes. RECENT FINDINGS: This report assesses the validity of a homeostatic toolkit to measure subjectively perceived hunger and its relationship to the developing processes of satiation (control of meal size) and satiety (control of the post-eating period). The capacity of a procedure to measure the influence of hedonic processes on food intake is also evaluated. A major issue is the relationship between the pattern of eating behaviour (influenced by the underlying drive to eat and the inhibition induced by the act of eating itself) and the parallel underlying profile of hormonal and other metabolic biomarkers. Increasing recognition is being given to individual variability in the expression of appetite, and the fact that the use of the average (mean) response conceals important information about the nature of appetite control. There is a growing interest in the identification of satiety phenotypes that operate in parallel to metabolic phenotypes. Interestingly, energy expenditure (metabolic and behavioural) contributes to an energy balance framework for understanding energy intake (appetite).


Assuntos
Apetite , Obesidade/epidemiologia , Saciação , Regulação do Apetite , Biomarcadores/sangue , Composição Corporal , Ingestão de Alimentos/psicologia , Metabolismo Energético , Hormônios Gastrointestinais/sangue , Comportamentos Relacionados com a Saúde , Humanos , Fome , Refeições , Obesidade/psicologia , Hormônios Peptídicos/sangue , Tamanho da Porção
4.
Transl Res ; 210: 8-25, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30953609

RESUMO

Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from ß-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-ß levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.


Assuntos
Diabetes Mellitus Tipo 1/imunologia , Diabetes Mellitus Tipo 1/patologia , Proteínas Semelhantes a Angiopoietina/sangue , Biomarcadores/sangue , Índice de Massa Corporal , Estudos de Casos e Controles , Criança , Diabetes Mellitus Tipo 1/sangue , Progressão da Doença , Feminino , Humanos , Memória Imunológica , Subpopulações de Linfócitos/metabolismo , Masculino , Monócitos/metabolismo , Hormônios Peptídicos/sangue , Projetos Piloto , Indução de Remissão , Fator de Crescimento Transformador beta/sangue
5.
Biomed Res Int ; 2019: 4504302, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30834265

RESUMO

Background: Extramedullary hematopoiesis (EMH) is common in non-transfusion-dependent thalassemia (NTDT) patients. Clinical presentations of EMH vary as MRI screening is not feasible. Hence, serum biomarkers are used to predict the risk of EMH. Materials and Methods: 52 NTDT patients, including 26 EMH (+) and 26 EMH (-), together with 26 healthy controls, were enrolled in this case-control study from 2013 to 2016. EMH was confirmed by computed tomography or MRI. Demographic, transfusion, genetic, laboratory, and liver iron concentration (LIC) data, as well as clinical complications, were analyzed. Results: EMH (+) patients had significantly higher serum ferritin (SF), growth differentiation factor 15 (GDF15), and erythropoietin (EPO) levels compared with EMH (-) patients and controls. The levels of erythroferrone (ERFE), hepcidin, and sTfR did not differ significantly between EMH (+) and EMH (-) patients (p>0.05). In NTDT patients, serum ERFE was not related to SF, LIC, hepcidin, sTfR, EPO, GDF15, and Hb levels. GDF15, EPO concentrations, and GDF15 to sTfR and GDF15 to EPO ratios are able to determine the presence of EMH with considerable sensitivity and specificity. Conclusions: GDF15, EPO, and GDF15 to EPO and GDF15 to sTfR ratios are potential biomarkers for the early prediction of NTDT in patients who are at risk for EMH.


Assuntos
Antígenos CD/sangue , Eritropoetina/sangue , Fator 15 de Diferenciação de Crescimento/sangue , Hematopoese Extramedular/genética , Receptores da Transferrina/sangue , Talassemia/sangue , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Eritropoese/genética , Feminino , Ferritinas/sangue , Hematopoese Extramedular/fisiologia , Hepcidinas/sangue , Homeostase/genética , Humanos , Ferro/metabolismo , Imagem por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Hormônios Peptídicos/sangue , Fatores de Risco , Talassemia/complicações , Talassemia/diagnóstico por imagem , Talassemia/fisiopatologia , Tomografia Computadorizada por Raios X
6.
Gynecol Endocrinol ; 35(3): 190-197, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30614305

RESUMO

The association between circulating betatrophin levels and polycystic ovary syndrome (PCOS) is controversial and the studies in the literature are inconsistent. The aim of our study was to systematically review and meta-analyze all available literature comparing circulating betatrophin levels between human PCOS patients and controls. Relevant studies were retrieved by online database and manual searching. A total of 11 studies were included in this meta-analysis. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. Meta-analysis of correlations was performed for the associations of betatrophin with anthropometric, lipid and hormonal covariates in PCOS patients. The results indicated that the betatrophin levels were significantly elevated in PCOS patients as compared to non-PCOS controls (SMD = 0.73, 95% CI = 0.22-1.24, Z = 2.83, p = .005). A one-study leave-out sensitivity analysis indicated that no single study had a significant influence on the overall outcome, suggesting the robustness of this meta-analysis. Our sub-group analysis indicated that this increase in betatrophin concentrations was regardless of normo-weight or obese body mass index (BMI) and insulin resistance might have an important role. There were significant positive correlations of betatrophin with age, free androgen index and free-testosterone in PCOS patients. In summary, regardless of BMI, the circulatory betatrophin levels are elevated in PCOS patients compared to controls. PCOS patients with higher insulin resistance had substantially higher circulating betatrophin concentrations.


Assuntos
Proteínas Semelhantes a Angiopoietina/sangue , Índice de Massa Corporal , Resistência à Insulina/fisiologia , Hormônios Peptídicos/sangue , Síndrome do Ovário Policístico/sangue , Biomarcadores/sangue , Feminino , Humanos
7.
Poult Sci ; 98(6): 2439-2447, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30668853

RESUMO

We evaluated the effect of photoperiod on ovarian morphology, reproductive hormone secretion, and hormone receptor mRNA expression in layer ducks during the pullet phase. A total of 480 71-d-old Jinding layer ducks were randomly divided into 5 groups that received 6L (hours of light):18D (hours of darkness), 8L:16D, 10L:14D, 12L:12D, or 14L:10D, respectively. Each group had 6 replicates with 16 birds each. The photoperiod feeding trial lasted 80 d until 150 d of age. The age at first egg (AFE), the total number, and weight of eggs increased linearly with increasing photoperiods (P < 0.05); lower values of AFE occurred with photoperiods ≥8 h, whereas a higher total number and weight of eggs occurred with photoperiods ≥10 h, compared with 6L:18D (P > 0.05). Oviduct weight, ovary percentage, and initial and bare stroma (weight and percentage) increased quadratically with increasing photoperiods (P < 0.05), and 10.24, 10.01, and 10.10 h were the optimal photoperiods for oviduct weight, bare stroma (follicles ≥2 mm in diameter removed) weight, and bare stroma percentage, respectively, as calculated from reliable regression equations (R2 ≥ 0.5791). Compared with 6L:18D, 10L:14D had a higher total large white follicle weight, small yellow follicle number, and weight (P < 0.05). In addition, higher serum levels of follicle-stimulating hormone, luteinizing hormone, and progesterone were observed with ≥10-h photoperiods (P < 0.05), as were levels of hormone receptor mRNA expression in ovarian follicles (P < 0.05), with the highest values for both measures at 10L:14D. In the hypothalamus, mRNA expression of gonadotropin-releasing hormone increased in ≥8-h photoperiods, with the highest value at 10L:14D. In contrast, gonadotropin-inhibitory hormone increased in photoperiods ≥12 h (P < 0.05). In conclusion, an appropriate photoperiod led to early sexual maturity and improved the development of reproductive organs and ovarian follicles through effects on reproductive hormones and their receptors; 10 to 10.24 h is an adequate photoperiod for layer ducks during the pullet phase.


Assuntos
Patos/fisiologia , Ovário/efeitos da radiação , Hormônios Peptídicos/sangue , Fotoperíodo , Progesterona/sangue , Maturidade Sexual/efeitos da radiação , Animais , Patos/anatomia & histologia , Patos/crescimento & desenvolvimento , Feminino , Hormônio Liberador de Gonadotropina/metabolismo , Hipotálamo/metabolismo , Ovário/anatomia & histologia , Ovário/crescimento & desenvolvimento , RNA Mensageiro/metabolismo , Distribuição Aleatória , Receptores de Peptídeos/metabolismo , Receptores de Progesterona/metabolismo , Maturidade Sexual/fisiologia
8.
Diabetes Metab Syndr ; 13(1): 458-463, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30641744

RESUMO

AIMS: Recently, it was suggested that betatrophin has a role in controlling pancreatic ß cell proliferation and lipid metabolism, however, its role in human subjects has not been established yet. The predicting role of betatrophin and MDA along with other biochemical indicators in type 2 diabetes mellitus (T2DM) in a sample of the Iraqi population was examined in the present investigation. METHODS: A total of 31 patients diagnosed with T2DM and 30 adult subjects without diabetes were matched in age and gender in a case-control study. Logistic and linear regression models were performed to examine the role of MDA and betatrophin in T2DM and triglyceride, respectively. RESULTS: The study confirmed a higher concentration of LDL (124.45 vs. 102.70 mg/dL; P = .001) and TG (191.13 vs. 103.83 mg/dL; P < .0001), insulin (18.40 vs. 10.97 µU/mL; P < .0001), and Hs. CRP (5.39 vs. 2.80 mg/L; P = .033) in diabetic patients compared to the controls. No significant difference in betatrophin and MDA was found between diabetic patients and non-diabetic healthy subjects. The study showed triglyceride as the only predictor of T2DM (P = .028). Similarly, total cholesterol (P < .0001), HDL (P = .001), LDL (P < .0003), and MDA (P = .010) were shown as predictors of triglyceride in diabetic patients. CONCLUSION: The present study that triglyceride is a direct and MDA is an indirect predictor for T2DM.


Assuntos
Proteínas Semelhantes a Angiopoietina/sangue , Biomarcadores/sangue , Diabetes Mellitus Tipo 2/sangue , Inflamação/complicações , Resistência à Insulina , Doenças Metabólicas/complicações , Estresse Oxidativo , Hormônios Peptídicos/sangue , Adulto , Estudos de Casos e Controles , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/etiologia , Feminino , Seguimentos , Humanos , Mediadores da Inflamação/sangue , Masculino , Pessoa de Meia-Idade , Prognóstico
9.
Endocrinol. diabetes nutr. (Ed. impr.) ; 66(1): 4-10, ene. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-175787

RESUMO

Introduction: Patients with HIV+ often present lipid disturbances. The role of ghrelin and obestatin in these lipid disturbances is not clear. The effect of antiretroviral (ART) drugs on those molecules is also unknown. This study measured ghrelin and obestatin levels, as well as metabolic markers, in patients with HIV+ before and after 36 weeks of ART. Material and methods: Twenty HIV-positive, ART-naïve patients who started a scheme consisting of tenofovir/emtricitabine+lopinavir/ritonavir were enrolled. Plasma samples were collected before and after 36 weeks of treatment. Serum ghrelin and obestatin levels were quantitated by ELISA; glucose, cholesterol, and triglyceride levels were measured by colorimetric and enzymatic methods, and cardiovascular risk was calculated by the atherogenic index of plasma (AIP). Results: All patients completed 36 weeks of ART. Total cholesterol (p<0.001), LDL-C (p=0.019), HDL-C (p=0.003), VLDL-C (p=0.002), and triglyceride levels (p=0.021) significantly increased after treatment. AIP revealed increased cardiovascular risk at baseline, which remained high after treatment. There was a statistically significant increase in obestatin level in the unpaired and paired analyses, while ghrelin levels only showed a trend to increase. Changes in ghrelin and obestatin levels positively correlated, but no correlation was seen with any metabolic parameter. Conclusion: After 36 weeks of ART, patients showed an altered lipid profile, but there were no significant changes in cardiovascular risk. Ghrelin and obestatin levels increased after 36 weeks of ART, but the increase was only significant for obestatin. Changes in ghrelin and obestatin positively correlate


Introducción: Los pacientes con VIH+ frecuentemente presentan alteraciones del perfil lípidico. El papel de ghrelina y obestatina en estas complicaciones no está claro. El efecto del tratamiento antirretroviral (TAR) en dichas moléculas es desconocido. Este estudio determinó los niveles de ghrelina y obestatina, así como los parámetros metabólicos en pacientes VIH+ antes y después de 36 semanas del TAR. Material y métodos: Participaron 20 pacientes VIH+, vírgenes a TAR, que iniciaron con un esquema de tenofovir/emtricitabina + lopinavir/ritonavir. Se tomaron muestras de plasma antes y después de 36 semanas de tratamiento. Los niveles séricos de ghrelina y obestatina fueron cuantificados por ELISA, los parámetros bioquímicos fueron determinados por métodos colorimétricos, se evaluó el riesgo cardiovascular por medio del índice aterogénico del plasma (AIP). Resultados: Los pacientes completaron 36 semanas del TAR. Los niveles de colesterol total (p<0,001), c-LDL (p=0,019), c-HDL (p=0,003), c-VLDL (p=0,002) y triglicéridos (p=0,021) mostraron un incremento estadísticamente significativo posterior al tratamiento. El AIP reveló un riesgo cardiovascular alto. Los niveles de obestatina se incrementaron significativamente en el análisis pareado y no pareado; y ghrelina solo mostró tendencia al incremento. Los cambios en ghrelina y obestatina correlacionaron positivamente, sin embargo no correlacionaron con los parámetros metabólicos. Conclusión: Los pacientes VIH+ mostraron un perfil lipídico alterado después de 36 semanas del TAR. Los niveles de ghrelina y obestatina se incrementaron tras 36 semanas del TAR. El riesgo cardiovascular es persistente. Los cambios en ghrelina y obestatina mostraron una correlación positiva


Assuntos
Humanos , Masculino , Feminino , Adulto , Antirretrovirais/farmacologia , HIV , Grelina/sangue , Hormônios Peptídicos/sangue , Antirretrovirais/uso terapêutico , HIV/metabolismo , Grelina/uso terapêutico , Hormônios Peptídicos/uso terapêutico , Dislipidemias/fisiopatologia
10.
Clin Chim Acta ; 489: 183-188, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29104036

RESUMO

BACKGROUND: Asprosin has been identified as a novel hormone enriched in white adipose tissue and is pathologically increased in insulin-resistant mice and humans. However, information regarding the role of asprosin in type 2 diabetes mellitus (T2DM) remains unavailable. Via conducting a hospital-based study, we purposed to ascertain the potential relationship between circulating asprosin concentrations and T2DM. METHODS: The study recruited 84 adults with T2DM and 86 controls with normal glucose tolerance. They matched in age, body mass index (BMI), and sex. Serum asprosin concentrations were measured via ELISA method. RESULTS: Compared to the controls, serum asprosin concentrations were significantly increased in the T2DM adults (P<0.001). As asprosin concentrations increased across its tertiles, the percentage of T2DM increased (39.28, 37.50, and 70.68%; P value for trend <0.001). Multivariate logistic regression models demonstrated that compared with the 1st tertile of asprosin, the odds ratio of T2DM was 3.278(95% CI 1.053-10.200, P=0.040) for the 3rd tertile after adjustment for potential confounders. Area under ROC curve of asprosin (sex and age adjusted) for predicting the presence of T2DM was 0.707[95% CI 0.628-0.786]. Finally, multiple stepwise regression analysis indicated that fasting glucose and triglyceride were independently associated with serum asprosin in T2DM. CONCLUSIONS: Asprosin concentrations are increased in adults with T2DM. The results suggest that asprosin might serve as a risk factor associated with the pathogenesis of T2DM, but not an ideal biomarker for predicting T2DM.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Jejum/sangue , Proteínas dos Microfilamentos/sangue , Fragmentos de Peptídeos/sangue , Hormônios Peptídicos/sangue , Triglicerídeos/sangue , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
11.
Gynecol Endocrinol ; 35(3): 224-227, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30241452

RESUMO

Betatrophin is defined as a new marker in glucose homeostasis and lipid metabolism. We aimed to investigate the role of serum betatrophin in full-blown polycystic ovary syndrome (PCOS) patients and 47-aged healthy women, 51 full-blown PCOS patients were included in this cross-sectional study. Betatrophin concentrations were significantly lower in PCOS group and displayed a positive correlation only with serum tryglyceride in control group (p < .05). A cutoff level (464.5 ng/L) was determined for betatrophin according to Receiver Operating Characteristic curve. Using this value, 64.7% of PCOS patients were classified as below the cutoff and in this group betatrophin was found to correlate negatively with fasting glucose, fasting insulin, and homeostasis model assessment of insulin resistance (p = .038, p = .020, and p = .014, respectively), and positively with total testosterone (p = .041). In the rest of PCOS cases (35.3%) who had betatrophin higher than cutoff, positive correlation was found with low-density lipoprotein cholesterol (p = .009). In conclusion, betatrophin levels are reduced in full-blown PCOS patients who had worse metabolic phenotype.


Assuntos
Proteínas Semelhantes a Angiopoietina/sangue , Glicemia , Resistência à Insulina/fisiologia , Insulina/sangue , Hormônios Peptídicos/sangue , Síndrome do Ovário Policístico/sangue , Adulto , Biomarcadores/sangue , Índice de Massa Corporal , Estudos Transversais , Feminino , Humanos , Estudos Prospectivos , Adulto Jovem
12.
Gynecol Endocrinol ; 35(3): 220-223, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30325247

RESUMO

Asprosin associated with insulin resistance is a newly discovered peptide hormone. The peptide promotes hepatic glucose production. Polycystic ovary syndrome (PCOS) is a metabolic disorder. Insulin resistance plays a vital role in the pathogenesis of the disease. The aim of this study was to discover the association between insulin resistance and asprosin in women with PCOS. We recruited 78 subjects with PCOS and 78 age-matched and body mass index (BMI)-matched controls into this cross-sectional study. Circulating asprosin levels were validated using ELISA method. We also determined metabolic and hormonal parameters of the involved subjects. We found that circulating asprosin levels were elevated in women with PCOS with respect to controls. Asprosin levels showed a positive correlation with insulin resistance, BMI, and free androgen index (FAI). Moreover, subjects with the highest tertile of asprosin levels represented increased odds of having PCOS as compared to those subjects with the lowest tertile asprosin levels. Increased asprosin levels resulted to high possibility of having PCOS risk associated with insulin resistance.


Assuntos
Índice de Massa Corporal , Resistência à Insulina/fisiologia , Proteínas dos Microfilamentos/sangue , Fragmentos de Peptídeos/sangue , Hormônios Peptídicos/sangue , Síndrome do Ovário Policístico/sangue , Adulto , Glicemia , Estudos Transversais , Feminino , Humanos , Insulina/sangue , Testosterona/sangue , Adulto Jovem
13.
J Atheroscler Thromb ; 26(6): 573-581, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30518729

RESUMO

AIM: Betatrophin, a recently identified circulating adipokine, affects lipid and glucose metabolism. However, association between plasma betatrophin levels and atherosclerotic diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD), has not been elucidated. METHODS: We investigated plasma betatrophin levels in 457 patients undergoing elective coronary angiography who also had ankle-brachial index (ABI) test for PAD screening. RESULTS: Of the 457 study patients, CAD was present in 241 patients (53%) (1-vessel [1-VD], n=99; 2-vessel [2-VD], n=71; 3-vessel disease [3-VD], n=71). Compared to 216 patients without CAD, 241 with CAD had higher betatrophin levels (median 1120 vs. 909 pg/mL, p<0.001). A stepwise increase in betatrophin levels was found depending on the number of >50% stenotic coronary vessels: 909 in CAD(-), 962 in 1-VD, 1097 in 2-VD, and 1393 pg/ml in 3-VD (p<0.001). Betatrophin levels correlated with the number of >25% stenotic segments (r=0.24, p<0.001). PAD (ABI<0.9) was found in 41 patients (9%). Plasma betatrophin levels were also significantly higher in 41 patients with PAD than in 416 without PAD (1354 vs. 981 pg/mL, p<0.001). In the multivariate analysis, betatrophin levels were not a factor for CAD, but they were a significant factor for 3-VD and PAD independent of atherosclerotic risk factors. The odds ratios for 3-VD and PAD were 1.06 (95%CI=1.01-1.11) and 1.07 (95%CI=1.01-1.13) for a 100-pg/mL increase in betatrophin levels, respectively (p<0.05). CONCLUSION: Plasma betatrophin levels were associated with the presence and severity of CAD and PAD, suggesting betatrophin has a role in atherosclerosis.


Assuntos
Proteínas Semelhantes a Angiopoietina/sangue , Biomarcadores/sangue , Doença da Artéria Coronariana/sangue , Hormônios Peptídicos/sangue , Doença Arterial Periférica/sangue , Idoso , Angiografia Coronária , Doença da Artéria Coronariana/complicações , Doença da Artéria Coronariana/patologia , Estudos Transversais , Feminino , Seguimentos , Humanos , Masculino , Doença Arterial Periférica/complicações , Doença Arterial Periférica/patologia , Prognóstico , Fatores de Risco
15.
Mediators Inflamm ; 2018: 7375294, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30524197

RESUMO

Asprosin is a white adipose tissue-derived hormone that increases abnormally in mammals with insulin resistance. However, the role of asprosin in polycystic ovary syndrome (PCOS), a disease partly characterized by insulin resistance, and its potential connection with type 2 diabetes mellitus (T2DM) and PCOS has not been thoroughly elucidated to date. To investigate the association of asprosin with metabolic profiles, sex-related hormones, or inflammation in females with T2DM or PCOS, plasma asprosin and metabolic indicators were measured in 66 healthy females, 53 female patients with T2DM, and 41 patients with PCOS. Spearman's correlation analysis and binary logistic regression analysis models were used. Plasma asprosin was significantly higher in T2DM females than in healthy subjects (P < 0.001) and was positively correlated with fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and HOMA-IR (P < 0.05). Asprosin in PCOS subjects was also higher than in healthy subjects (P < 0.001) but lower than in T2DM subjects (P < 0.05), and it was positively correlated with FBG, HbA1c, HOMA-IR, LDL-c, APOB, APOE, and testosterone (P < 0.05). The BMI-categorized subgroups of PCOS subjects also showed correlations of asprosin with metabolic profiles and sex-related hormones. Binary logistic regression analysis revealed that plasma asprosin level acted as an independent risk factor for T2DM or PCOS. These findings suggest the correlation of plasma asprosin level with glucose metabolism, lipid metabolism, sex-related hormones, and inflammation in females, supporting asprosin as a potential predictive factor for females with metabolic-related diseases. This trial is registered with ChiCTR-ROC-17010719.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Proteínas dos Microfilamentos/sangue , Fragmentos de Peptídeos/sangue , Hormônios Peptídicos/sangue , Síndrome do Ovário Policístico/sangue , Jejum/sangue , Feminino , Hemoglobina A Glicada/metabolismo , Humanos , Metabolismo dos Lipídeos/fisiologia , Modelos Logísticos , Fatores de Risco , Testosterona/sangue
16.
Respir Res ; 19(1): 239, 2018 Dec 04.
Artigo em Inglês | MEDLINE | ID: mdl-30514305

RESUMO

BACKGROUND: The main causes of COPD are tobacco smoking (COPD-TS) and biomass smoke exposure (COPD-BS). COPD-TS is known to induce changes in adipokines, incretins, and peptide hormones, frequent biomarkers of inflammation; however, it is unknown if similar changes occur in COPD-BS. METHODS: Clinical and physiological characteristics, and serum concentration of C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin, and visfatin were measured in women with COPD-BS, COPD-TS, and healthy controls. Data were compared with one-way ANOVA and Tukey's post hoc test; nonparametric were expressed as median (interquartile ranges), with Kruskal-Wallis and Dunn's post-hoc test. Multivariate analysis, age, BMI, MS, and FEV1% pred with levels of inflammatory mediators in COPD women. RESULTS: FEV1% pred, FVC% pred, and FEV1/FVC ratio were decremented in COPD. In COPD-TS increased C-peptide, ghrelin, GIP, GLP-1, and leptin, and reduced glucagon, PAI-1, resistin, and visfatin. In COPD-BS enlarged ghrelin, insulin, leptin, and PAI-1 comparatively with COPD-TS and control, while C-peptide and GLP-1 relatively with controls; conversely, glucagon, and resistin were reduced. Multivariate analysis showed association of ghrelin, insulin, PAI-1, and visfatin with BS exposure. CONCLUSIONS: women with COPD-BS have a distinct profile of adipokines, incretins, and peptide hormones, and specifically with ghrelin, insulin, PAI-1, and visfatin related to BS exposure.


Assuntos
Adipocinas/sangue , Fumar Cigarros/sangue , Incretinas/sangue , Hormônios Peptídicos/sangue , Doença Pulmonar Obstrutiva Crônica/sangue , Fumantes , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Fumar Cigarros/epidemiologia , Feminino , Humanos , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/epidemiologia
17.
Cardiovasc Diabetol ; 17(1): 142, 2018 11 08.
Artigo em Inglês | MEDLINE | ID: mdl-30409151

RESUMO

BACKGROUND: It is well known that angiopoietin-like protein 8 (ANGPTL8) exerts its effects on lipid metabolism through the inhibition of lipoprotein lipase and subsequent elevation of plasma triglyceride. However, it is not clear whether ANGPTL8 could affect lipid metabolism via other pathways. The study was aimed to investigate the effects of ANGPTL8 on the function of high-density lipoprotein (HDL), which plays a protective role in atherosclerosis progression. METHODS: Two hundred and ten subjects were recruited. Plasma ANGPTL8 was measured by enzyme-linked immunosorbent assays. Cholesterol efflux capacity was chosen as the biomarker of HDL function and measured via H3-cholesterol loading THP-1 cell models. RESULTS: ANGPTL8 exhibited no significant difference between CAD group and nonCAD group, but ANGPTL8 in DM group was significantly higher than that in the nonDM group [568.3 (406.2-836.8) vs 458.2 (356.8-755.6), P = 0.023]. Compared to controls, subjects in CAD group and DM group exhibited significantly lower cholesterol efflux capacity [CAD: 14.58 ± 2.06 vs 12.51 ± 2.83%, P < 0.0001; DM: 13.62 ± 2.57 vs 12.34 ± 3.16%, P = 0.0099]. ANGPTL8 was inversely correlated with cholesterol efflux capacity (r = - 0.188, P < 0.01). Regression analysis revealed that plasma ANGPTL8 was an independent contributor to cholesterol efflux capacity (standardized ß = - 0.143, P = 0.023). CONCLUSION: ANGPTL8 presents a negative effect on HDL-mediated cholesterol efflux capacity.


Assuntos
Síndrome Coronariana Aguda/sangue , Proteínas Semelhantes a Angiopoietina/sangue , HDL-Colesterol/sangue , Diabetes Mellitus Tipo 2/sangue , Macrófagos/metabolismo , Hormônios Peptídicos/sangue , Síndrome Coronariana Aguda/diagnóstico , Idoso , Transporte Biológico , Estudos de Casos e Controles , Diabetes Mellitus Tipo 2/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Células THP-1
18.
J Clin Psychopharmacol ; 38(6): 622-626, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30300290

RESUMO

BACKGROUND: Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested that SGAs increase appetite leading to weight gain. The present objective was to perform a pilot study to investigate appetite and satiety hormones in SGA-treated (risperidone or quetiapine) and SGA-naive children with similar mental health conditions. METHODS: Oral glucose tolerance tests (OGTTs) were conducted in SGA-naive (n = 18), risperidone-treated (n = 20), and quetiapine-treated (n = 16) children recruited from the British Columbia Children's Hospital Psychiatry Department. Over 5 time-points during the OGTT, appetite questionnaires using a visual analogue scale were administered, and blood was collected to measure ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, glucagon-like protein 1, leptin, and adiponectin. Mixed model analyses were conducted to examine between-group differences. RESULTS: The children were similar in age, psychiatric diagnosis, and global assessment of functioning scores. Body mass index z-scores were also similar between groups. Appetite was increased during the OGTT in the risperidone-treated compared with the SGA-naive group for 2 questions ("How strong is your desire to eat"; P = 0.003 and "How much food do you think you can eat"; P = 0.028). No differences in satiety hormones were observed between the 3 groups. CONCLUSIONS: Risperidone treatment in youth is associated with elevated appetite during an OGTT, with no differences in gut peptides or adipocytokines to explain risperidone's effect on appetite. Further research is needed to explore other mediators of weight gain and metabolic dysfunction in SGA-treated youth.


Assuntos
Antipsicóticos/efeitos adversos , Apetite/efeitos dos fármacos , Transtornos Mentais/tratamento farmacológico , Hormônios Peptídicos/efeitos dos fármacos , Fumarato de Quetiapina/efeitos adversos , Risperidona/efeitos adversos , Saciação/efeitos dos fármacos , Adolescente , Criança , Estudos Transversais , Feminino , Humanos , Masculino , Transtornos Mentais/sangue , Hormônios Peptídicos/sangue , Projetos Piloto
19.
Dis Markers ; 2018: 1679690, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30254709

RESUMO

Background: Spexin (SPX) is a novel peptide that is implicated in obesity and related energy homeostasis in animals and adult humans. Little is known about its role in adults' overall cardiometabolic health. The aim of the study was to determine whether circulating levels of spexin (SPX) is associated with components of metabolic syndrome (MetS). Methods: The present cross-sectional study included 124 participants (41 males and 83 females; aged 42.4 ± 10.3 y) (MetS group) and 136 (21 male and 115 females; aged 33.1 ± 8.7 y) (non-MetS group). SPX was measured using commercially available assays. Anthropometrics were measured, and fasting serum glucose levels as well as lipid profile were quantified routinely. MetS was screened according to common definitions. Results: SPX levels were significantly lower in participants with MetS vs. non-MetS (0.18 ng/ml (0.13-0.24) vs. 0.26 ng/ml (0.17-0.50); p < 0.001). In all MetS definitions used, SPX was significantly lower in the MetS group than the non-MetS group using the WHO definition after adjustment for age and BMI. Stratification according to sex revealed that SPX was associated with MetS only in women, and this significance was lost after adjustment for age and BMI. Conclusions: Lower circulating levels of SPX in adults are modestly associated with components of MetS and are sex-specific. Further studies are necessary to determine whether SPX is associated with harder outcomes such as atherosclerosis and diabetes in the general population.


Assuntos
Síndrome Metabólica/sangue , Hormônios Peptídicos/sangue , Adolescente , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Humanos , Masculino , Pessoa de Meia-Idade
20.
Med Princ Pract ; 27(6): 549-554, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30184546

RESUMO

BACKGROUND/AIMS: Spexin is a novel peptide which has a potential role as a biomarker of insulin resistance, diabetes, and obesity. Our aim was to measure spexin levels in lean type 1 diabetic patients and its relevance to glycemic parameters without the presence of obesity or insulin resistance. SUBJECTS AND METHODS: This cross-sectional study included 29 type 1 and 30 type 2 diabetic patients and a control group of 23 healthy subjects with adjusted age, sex, and body mass index (BMI). Height and weight were measured using standard techniques. Glucose levels, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum cortisol levels, and spexin levels were measured in each patient. RESULTS: The median fasting serum spexin levels were significantly lower in patients with type 1 and type 2 diabetes than in control subjects (p = 0.008 and p = 0.041, respectively). Spexin levels were not correlated with glycemic parameters, lipids, BMI, cortisol levels, and thyroid-stimulating hormone (p > 0.05). Only age turned out to be correlated with spexin levels in patients with type 1 diabetes when we analyzed the groups separately. Regression models, including age and diabetes duration, revealed no association between age and spexin levels. Regression models, including cortisol, BMI, and HbA1c, revealed no association with spexin levels within each group. CONCLUSION: The presence of type 1 diabetes is associated with lower spexin levels, independent of glucose, lipid parameters, and BMI. The expression of spexin in the pancreas apart from the current glycemic control of the patients may be the main determinant of spexin levels in type 1 diabetic patients.


Assuntos
Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 2/sangue , Hormônios Peptídicos/sangue , Adulto , Análise de Variância , Biomarcadores/sangue , Índice de Massa Corporal , Estudos Transversais , Feminino , Hemoglobina A Glicada/análise , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Turquia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA